Clinical Trials

Study closed to enrollment

Inclusion Criteria:

• Adult patients, ≥ 18 years of age
• Patients with basal cell carcinoma (BCC) who meet either of the following definitions:
  • Patients who were determined with advanced disease (aBCC) within 90 days prior to study enrollment, have not been diagnosed with basal cell carcinoma nevus syndrome (BCCNS) and have not been treated with an investigational or approved hedgehog pathway inhibitor
  • Patients with aBCC who have not been diagnosed with BCCNS and who were previously treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)
  • Patients with BCCNS who either have aBCC or multiple BCCs of any stage as defined by protocol (may include patients previously enrolled in Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP))
  • Patients who have had 10 or more clinically and/or histologically-determined non-advanced BCCs in the 2 years prior to study enrollment and at least 2 BCCs still clinically visible ≤ 90 days prior to enrollment

Exclusion Criteria:

• Participation in a clinical trial within 90 days prior to study enrollment that has either involved treatment of aBCC or involved treatment with an investigational or approved hedgehog pathway inhibitor, except for patients treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)